Monoclonal Antibody to 25-Hydroxyvitamin D3 (HVD3)
| Code | Size | Price |
|---|
| MAA915Ge21-20ul | 20ul | £94.00 |
Quantity:
| MAA915Ge21-100ul | 100ul | £180.00 |
Quantity:
| MAA915Ge21-200ul | 200ul | £244.00 |
Quantity:
| MAA915Ge21-1ml | 1ml | £563.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Multiple species
Applications:
- Antibody Production
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Immunoprecipitation (IP)
- Radial Immunodiffusion Assay
Documents
Further Information
Alternative Names:
25-HVD3; 25HVD3; Calcifediol; Calcidiol; H-VD3; 25-Hydroxycholecalciferol; 25-Hydroxy Vitamin D3; 25(OH)D
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
25-Hydroxyvitamin D3
Potency (Clone Number):
D1
Reactivity:
Ge;
Source:
Monoclonal antibody preparation
Usage:
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OVA Conjugated 25-Hydroxyvitamin D3 (HVD3) | CPA915Ge21 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||